Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Revenue: 2021-2025

Historic Revenue for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to -$344,000.

  • Allogene Therapeutics' Revenue fell 244.00% to -$344,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$843,000, marking a year-over-year decrease of 2308.57%. This contributed to the annual value of $22,000 for FY2024, which is 76.84% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Revenue stood at -$344,000, which was down 28.36% from -$268,000 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Revenue high stood at $75.7 million for Q4 2021, and its period low was -$344,000 during Q3 2025.
  • Its 3-year average for Revenue is -$82,600, with a median of -$30,000 in 2023.
  • In the last 5 years, Allogene Therapeutics' Revenue soared by 45.45% in 2022 and then tumbled by 781.82% in 2025.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Revenue stood at $75.7 million in 2021, then plummeted by 99.97% to $26,000 in 2022, then declined by 19.23% to $21,000 in 2023, then tumbled by 485.71% to -$81,000 in 2024, then crashed by 244.00% to -$344,000 in 2025.
  • Its last three reported values are -$344,000 in Q3 2025, -$268,000 for Q2 2025, and -$150,000 during Q1 2025.